Loading stock data…
NAGE
$3.98-0.19 (-4.56%)
Market ClosedLast close May 11
Niagen Bioscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Niagen Bioscience, Inc. in the Healthcare sector is trading at $3.98. The stock is currently near its 52-week low of $3.94, remaining 41.5% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why NAGE maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.98
Potential Downside
9.8%
Whystock Fair Value$3.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$12.80+221.6%
Range$10.00 – $18.00
Fundamentals
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$402.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.10
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.17%
Volume
Today's trading volume
1.95M
Recent News
Spotlight On Promising Penny Stocks For May 2026
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
Microvast Holdings And 2 Other Penny Stocks Worth Watching
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. Though the term 'penny stock' might sound like a relic of past trading days, the opportunity it points to is still relevant. These smaller or newer companies can offer a mix of affordability and growth potential when paired with strong financials, providing investors a chance to discover hidden value in quality stocks.
Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives
Niagen Bioscience (NAGE) is back on investor radars after reporting first quarter 2026 earnings, with sales of US$31.47 million and net income of US$6.32 million from continuing operations. See our latest analysis for Niagen Bioscience. Despite launching Niagen Plus and expanding its injectable and IV partnerships, Niagen Bioscience’s share price has come under pressure, with the stock down 33.28% year to date and the 1 year total shareholder return falling 55.59%, although the 3 year total...
Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus?
In early May 2026, Niagen Bioscience, Inc. reported first-quarter net sales of US$31.47 million and net income of US$6.32 million, while also launching its clinician-directed Niagen Plus telehealth platform and prescription-only At-Home Injection Kit in the U.S. to expand access to pharmaceutical-grade Niagen. Together with the earlier partnership with Olympia Pharmaceuticals to compound and distribute Niagen IV and injectable products, these moves signal a sharper focus on higher-value NAD+...
May 2026 Penny Stocks Worth Watching
The United States market has shown robust growth, climbing 3.2% in the last week and up 31% over the past year, with earnings expected to grow annually by 16%. In this context of strong market performance, identifying stocks with solid financial foundations is crucial for investors looking to capitalize on potential gains. While the term "penny stocks" might seem outdated, these often-overlooked smaller or newer companies can offer unique opportunities for growth when supported by strong...